{"id":"W4391100832","doi":"10.1093/eurheartj/ehad889","title":"Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial","year":2024,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Fatty Acid Research and Health","field":"Nursing","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"Daiichi Sankyo Europe; St. Jude Medical; HLS Therapeutics; Idorsia Pharmaceuticals; Assistance publique-Hôpitaux de Paris; Pfizer; Moderna; Medicines Company; Regado Biosciences; Belvoir Media Group; Amarin Pharma; Novo Nordisk; MyoKardia; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; National Institutes of Health; Regeneron Pharmaceuticals; Duke Clinical Research Institute; Eisai; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; Amryt Pharma; Esperion Therapeutics; Alnylam Pharmaceuticals; Amgen; Sanofi; American Heart Association","keywords":"Medicine; Acute coronary syndrome; Internal medicine; Cardiology; Myocardial infarction","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009462982,0.001272252,0.002176188,0.0002948002,0.0002480763,0.0007908059,0.0006093897,0.00113343,0.004885071],"category_scores_gemma":[0.001529617,0.0002306523,0.001306293,0.0004430561,0.0004978169,0.0004914344,0.0004819972,0.002185417,0.0008076706],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003566783,"about_ca_system_score_gemma":0.0004543371,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001002811,"about_ca_topic_score_gemma":0.002073841,"domain_scores_codex":[0.9996118,0.0001981363,0.00002244116,0.00004715355,0.00005241315,0.00006815107],"domain_scores_gemma":[0.9996819,0.00007104601,0.0001115252,0.00002915912,0.00002502794,0.00008131278],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8847365,0.00539438,0.003345866,0.005308076,0.002998251,0.0001790338,0.0001218584,0.0007808866,0.004434565,0.001158162,0.01258133,0.0789611],"study_design_scores_gemma":[0.910806,0.05328203,0.01871763,0.0007714822,0.00424901,0.0002553322,0.00007766248,0.0009704636,0.0009565885,0.0009106591,0.008952117,0.00005104959],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8999961,0.06306583,0.001283978,0.003684793,0.001580684,0.003296484,0.005187626,0.00042339,0.02148116],"genre_scores_gemma":[0.9467669,0.02599221,0.002512062,0.005091346,0.002061103,0.004577527,0.006138574,0.00007077753,0.006789565],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004885071,"threshold_uncertainty_score":0.01634222,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08612836554330867,"score_gpt":0.3915233961640737,"score_spread":0.305395030620765,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}